Top Markets
#1 Akedo Akedo +73.71%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.71%
#4 Cross Cross +43.52%
#5 Black Phoenix Black Phoenix +33.78%
#6 Cap Cap +25.61%
#7 Velvet Velvet +25.32%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.62%
#9 DoubleZero DoubleZero +12.53%
#10 Humanity Humanity +10.30%
Coin of the day
Akedo Akedo
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Aceragen, Inc. Aceragen, Inc.

Aceragen, Inc.

ACGN
Rangering i aksjer #39037
Aceragen, Inc., a biopharmaceutical firm in its clinical development phase,... Aceragen, Inc., a biopharmaceutical firm in its clinical development phase, operates out of Exton, Pennsylvania, and was founded in 1989. The company, which transitioned from Idera Pharmaceuticals, Inc. and adopted its current name in January 2023, concentrates on the discovery, advancement, and bringing to market of therapeutic agents for uncommon lung and autoimmune conditions exclusively within the United States. Its product development pipeline includes ACG-701, currently undergoing Phase 2 clinical evaluation for both cystic fibrosis pulmonary exacerbations and melioidosis, as well as ACG-801, which is being developed to address Farber disease. Moreover, Aceragen maintains a partnership and option agreement with Scriptr Global, Inc. This collaboration aims to pinpoint, research, and cultivate gene therapy options intended for the management, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia.
Aksjekurs
$0.38
Sist synkronisert: 2023-09-01
Markedsverdi
$677.16K
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Aceragen, Inc. (ACGN)

Kategori

Healthcare
Inntekter for Aceragen, Inc. (ACGN)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Aceragen, Inc. er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Aceragen, Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE